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Abstract
Macrophage Scavenger Receptor A (SR-A) is a major non-opsonic receptor for Neisseria meningitidis on mononuclear
phagocytes in vitro, and the surface proteins NMB0278, NMB0667, and NMB1220 have been identified as ligands for SR-A. In
this study we ascertain the in vivo role of SR-A in the recognition of N. meningitidis MC58 (serogroup B) in a murine model of
meningococcal septicaemia. We infected wild-type and SR-A
2/2 animals intraperitoneally with N. meningitidis MC58 and
monitored their health over a period of 50 hours. We also determined the levels of bacteraemia in the blood and spleen,
and measured levels of the pro-inflammatory cytokine interleukin-6 (IL-6). The health of SR-A
2/2 animals deteriorated more
rapidly, and they showed a 33% reduction in survival compared to wild-type animals. SR-A
2/2 animals consistently
exhibited higher levels of bacteraemia and increased levels of IL-6, compared to wild-type animals. Subsequently, we
constructed a bacterial mutant (MC58-278-1220) lacking two of the SR-A ligands, NMB0278 and NMB1220. Mutation of
NMB0667 proved to be lethal. When mice were infected with the mutant bacteria MC58-278-1220, no significant differences
could be observed in the health, survival, bacteraemia, and cytokine production between wild-type and SR-A
2/2 animals.
Overall, mutant bacteria appeared to cause less severe symptoms of septicaemia, and a competitive index assay showed
that higher levels of wild-type bacteria were recovered when animals were infected with a 1:1 ratio of wild-type MC58 and
mutant MC58-278-1220 bacteria. These data represent the first report of the protective role of SR-A, a macrophage-
restricted, non-opsonic receptor, in meningococcal septicaemia in vivo, and the importance of the recognition of bacterial
protein ligands, rather than lipopolysaccharide.
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Introduction
The innate immune system is a first line of defence against
invading pathogens and macrophages play an integral role in the
innate immune defence against bacterial infection. This is based
on the recognition of conserved microbial structures, termed
pathogen-associated molecular patterns (PAMPs), by a range of
pattern recognition receptors (PRRs). Macrophages (MQ) express
different classes of innate PRRs with diverse functions, including
the phagocytic Scavenger receptors (SRs) [1]. One of the receptors
belonging to this family is the class A scavenger receptor (SR-A),
which has been shown to recognise a range of polyanionic
molecules [2]. SR-A is a trimeric type II transmembrane
glycoprotein consisting of a cytoplasmic tail, transmembrane
domain, spacer region, a-helical coiled coil domain, collagenous
domain and C-terminal cysteine-rich domain. SR-A expression is
mostly restricted to macrophages and is not found on polymor-
phonuclear neutrophils or monocytes [3]. Recently, the expression
of SR-A was shown on mast cells [4] and specific sub-populations
of bone marrow-derived dendritic cells (DC) and splenic DC [5].
Selected endothelial cells and smooth muscle cells within
atherosclerotic plaques also express SR-A [6].
The Scavenger receptors play an important role in microbial
recognition and clearance, and SR-A has been shown to bind both
Gram-positive and Gram-negative bacteria [7]. Hampton and
colleagues first proposed that SR-A might be involved in
antimicrobial host defence, based on their observation that SR-
A could bind lipid A, an integral part of lipopolysaccharide (LPS)
[8]. Subsequent studies showed that SR-A also recognises the
Gram-positive cell-wall component lipoteichoic acid (LTA) [9].
Furthermore, SR-A binds to different LTA structures with varying
specificity depending on their exposed negative surface charge.
Unmethylated bacterial CpG DNA, another major immunosti-
mulatory microbial product, is also recognised by SR-A [10].
Using a range of Gram-positive organisms, Dunne and co-workers
confirmed that both soluble and cell-associated forms of SR-A are
not only able to bind bacterial components, but can also recognise
intact live organisms [11]. SR-A has been shown to play a role in
both infection and inflammation. In vivo studies with three Gram-
positive organisms have shown that SR-A
2/2 mice are more
susceptible to infection. SR-A
2/2 animals exhibited deficient
clearance of bacteria from the liver and spleen in experimental
Listeria monocytogenes infection [12]. SR-A
2/2 mice also showed
increased susceptibility to Staphylococcus aureus and Streptococcus
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protective role of SR-A was proposed by Haworth et al., who
observed that SR-A
2/2 mice formed normal granulomas in
response to BCG (Bacille Calmette-Gue ´rin) priming [15].
However, these animals were more susceptible to endotoxic shock
as a result of increased pro-inflammatory cytokine secretion in
response to additional lipopolysaccharide (LPS) challenge. In
addition, SR-A has been shown to modulate chemokine levels in
specific acute inflammatory conditions to ensure an inflammatory
response of the appropriate magnitude [16].
Neisseria meningitidis is a Gram-negative obligate commensal
bacterium that colonises the human nasopharynx, however when
the bacterium crosses this barrier, it causes meningitis and rapid
septicaemia, particularly in young children and teenagers. We
have shown previously that uptake of N. meningitidis by macro-
phages is mediated almost exclusively via SR-A [17]. Interestingly,
experiments employing an N. meningitidis lpxA mutant revealed that
recognition of N. meningitidis by SR-A was independent of
lipopolysaccharide, and we identified three bacterial surface
protein ligands for SR-A, namely NMB0278, NMB0667 and
NMB1220 [18]. In this study we investigated the in vivo role of SR-
A in inflammation in a murine meningococcal septicaemia model.
We also ascertained the contribution of the identified surface
protein ligands by constructing bacterial mutants in the SR-A
ligands and examining the effects of a double mutant in vivo.W e
show that SR-A knock-out mice are more susceptible to
septicaemia induced by N. meningitidis than wild-type mice, and
that for double knock-out bacteria lacking two SR-A ligands, these
effects are abrogated.
Materials and Methods
Chemicals and Reagents
Unless otherwise stated, all chemicals were from Sigma (Poole,
United Kingdom). Acetylated low density lipoprotein (AcLDL)
and Rhodamine Green X (RdGnX) were obtained from
Molecular Probes (Eugene, OR, USA). The TMB substrate
reagent set was purchased from BD Biosciences Pharmingen (San
Diego, CA). All culture media were from Gibco (Paisley, United
Kingdom). The rat monoclonal anti-CD68 monoclonal antibody
FA-11 was obtained from AbD Serotec (Kidlington, UK). The rat
monoclonal antibody against the 7/4 murine differentiation
antigen was generated in this laboratory [19]. M5114, the rat
monoclonal antibody recognising murine MHC-II was obtained
from R&D Systems (Abingdon, UK).
Bacterial Strains and Culture Conditions
The Neisseria meningitidis strains used in this study are listed in
Table 1. All strains were grown overnight at 37uC on brain-heart
infusion (BHI) medium (Oxoid), supplemented with Levinthal’s
reagent (10% vol/vol) and solidified with agar (1% [wt/vol];
Bioconnections), in an atmosphere of 5% CO2. For selection of
strains following transformation, kanamycin (75 mgm l
21)o r
erythromycin (6 mgm l
21) was added to the culture medium.
Escherichia coli strain DH5a was used to propagate recombinant
DNA constructs and was grown at 37uC on Luria-Bertani (LB)
medium supplemented with kanamycin (50 mgm l
21), erythromy-
cin (300 mgm l
21) or ampicillin (50 mgm l
21) where appropriate.
For fluorescent labelling, N. meningitidis were fixed with 70%
ethanol and labelled with RdGnX according to the manufacturer’s
instructions.
DNA Techniques
Recombinant DNA techniques were performed as described by
Sambrook et al. [20]. Restriction endonuclease and DNA
modifying enzymes were obtained from Boehringer Mannheim
or New England Biolabs and used according to the manufacturers’
instructions. Oligonucleotide primers were synthesised by Sigma-
Genosys. Standard polymerase chain reaction (PCR) amplifica-
tions were performed in 50 ml reaction volumes (final concentra-
tions: 20 mM Tris-HCl, pH 8.4; 50 mM KCl; 2.5 mM MgCl2;
0.4 mM forward primer; 0.4 mM reverse primer; 0.4 mM dNTPs)
with 1.25 U Taq recombinant polymerase (Invitrogen, Paisley,
UK) in a Master-Cycler (Eppendorf) gradient thermal cycler.
Thirty cycles of PCR were performed, each consisting of 1 min
denaturation at 94uC, 1 min annealing at typically 5uC below Tm
and 1 min extension at 72uC, with a final prolonged extension of
10 min at 72uC. Chromosomal DNA was prepared from N.
meningitidis strains as described previously [21]. A list of
oligonucleotide primers used in this study is given in Table 2.
Tricine-SDS-PAGE
Outer membrane vesicles were prepared from N. meningitidis
cells as described by Heckels and Williams et al [22,23]. Briefly,
cells were harvested from confluent growth of bacteria on 40 BHI
plates into 0.2 M lithium acetate (40 ml, pH 5.8) and extracted at
45uC in the presence of 2 mm glass beads (20 ml). Live bacteria
were removed by centrifugation at 13,00 g, 20 min, the
supernatant was then subjected to a repeat of this step. The outer
membranes were recovered by centrifugation at 11,000 g, 4uC,
2 h and the resuspended in 200 mld H 2O. The protein
concentration of the outer membranes was determined by
performing a Lowry MicroAssay (Sigma) according to the
manufacturer’s instructions. 15 mg of total protein was diluted in
dH2O and loaded in each well. Whole cell lysates were prepared
from N. meningitidis strains grown overnight, by harvesting and
resuspending cells in PBS and then adding the equivalent amount
of dissociation buffer (125 mM Tris, pH 6.8, 20% [v/v] glycerol,
3.9% [w/v] SDS, 10% b-mercaptoethanol, 0.04% [w/v] brom-
phenol blue). All samples were boiled at 100uC for 5 min. Samples
were separated by tricine-sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (T-SDS-PAGE) using 16.5% gels run at 30 mA
at 4uC for 18 hr [24], and were visualised by staining with silver
Author Summary
Macrophages are innate immune cells that provide a first
defence against infection. Several receptors on the surface
of macrophages mediate recognition of invading patho-
gens, and one of these is the Macrophage Scavenger
Receptor A (SR-A). SR-A recognises Neisseria meningitidis,a
bacterium that causes meningitis and septic shock, via
proteins on the surface of the bacterium. In this study we
investigated the interaction of SR-A with N. meningitidis in
a mouse model for septic shock, by infecting mice with N.
meningitidis and comparing a mouse strain expressing SR-
A with one that does not. The health of mice not
expressing SR-A deteriorated more rapidly and fewer
animals survived compared to those expressing SR-A.
Mice lacking SR-A had higher numbers of bacteria in their
blood and also produced more cytokines that can cause
septic shock. We also infected mice with bacteria that did
not express two of the proteins recognised by SR-A. In this
case, no differences in survival, levels of bacteria, or
cytokines were detected between animals that expressed
SR-A and those that did not. Therefore, we show that the
macrophage receptor SR-A is protective in the develop-
ment of septic shock induced by N. meningitidis.
SR-A Protects against Meningococcal Septicaemia
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Biosciences).
Disruption of Genes and Construction of Mutant Strains
To mutate the N. meningitidis NMB0278 gene, the gene was first
amplified by PCR from strain H44/76 chromosomal DNA with
oligonucleotide primers 278-f/278-r and cloned into the plasmid
pT7Blue (Novagen). A kanamycin resistance (kan
R) cassette was
excised from pUC4-kan by digestion with HincII and inserted into
the HincII site within the cloned NMB0278 gene. The resulting
construct, pT7-278-kan was used to transform N. meningitidis strain
MC58 as described previously [25]. Screening of transformants
was performed by PCR using primers designed to bind within the
kanR cassette and in the neighbouring gene to identify transfor-
mants containing a single, disrupted copy of NMB0278.
To mutate the N. meningitidis NMB0667 gene, the gene was first
amplified by PCR from strain H44/76 chromosomal DNA with
oligonucleotide primers 667-f/667-r and cloned into the plasmid
pT7Blue (Novagen). An erythromycin resistance cassette (ermC)
was excised from pER2 [26], by digestion with HincII and inserted
into the SmaI site within the cloned NMB0667 gene. The resulting
construct, pT7-667-ery, was used to transform N. meningitidis strain
MC58. Transformants were screened by PCR using primers
designed to bind within the ermC cassette and in the neighbouring
Table 1. List of N. meningitidis strains and plasmids used in this study.
N. meningitidis and Plasmids Description Source or Reference
MC58 L3 immunotyping reference strain, Serogroup B genome sequenced strain [37]
MC58-278 NMB0278 gene disrupted This study
MC58-1220 NMB1220 gene disrupted This study
MC58-278-1220 NMB0278 and NMB1220 genes disrupted This study
pT7Blue Cloning vector Novagen
pER2 Source of erythromycin resistance cassette [26]
pUC4-kan Source of kanamycin resistance cassette
pT7-278-kan Disrupted NMB0278 gene from MC58, cloned into pT7Blue This study
pT7-667-ery Disrupted NMB0667 gene from MC58, cloned into pT7Blue This study
pT7-1220-ery Disrupted NMB1220 gene from MC58, cloned into pT7Blue This study
doi:10.1371/journal.ppat.1000297.t001
Table 2. List of oligonucleotide primers used in this study.
Primer name Sequence (59R 39) Gene in which primer binds
278-f AGA CAC CTT GCC CTC GGC NMB0278
278-r TTC GCG TAC TTT GTC CGC C NMB0278
278-out-r TAT CGC GCC GTT ATG CCG NMB0279
278-out-f AAA GAT TGT GCG AAC AGC C NMB0278
Kan-5-out TCA AAA ATA TGG TAT TGA TAA T KanR [pUC4-kan]
Kan-3-out TGT AAC ATC ATT GGC AAC GC KanR [pUC4-kan]
667-f ATC GTA CTG TTT CTA GCT GTC G NMB0667
667-r ATG CGG TTT TGC CGC CCG NMB0667
667-f2 TCG CCG TTG TCG CCT AC NMB0667
667-out-f ACA CTG CTG GTC AGA CCC TGC NMB0666
667-out-r TGA ATG CG GAGA GTT CTT CC NMB0667
ery-if ACA TAA TAT AGA TAA AAT AAT GAC ermC [pER2]
ery-ir ATA ATT TAT AGC TAT TGA AAA GAG ermC [pER2]
1220-f TCA AAT CCT TTG TTG TCA TCC C NMB1220
1220-r TTT CAT ACC GGC AGA AAT CAG NMB1220
1220-5f ATA CGG GGC AAG AAG AGC TTG NMB1220
1220-5r TCG GTT ACT TGG AGA TCT ATG ATG CCG TC NMB1220
1220-3f TT CGA GCA ACT AGA TCT TGG CGA TTA CCC NMB1220
1220-3r TGA AGC GGA ATA CA ACCT TGC NMB1220
ery-eag-f GAT CCC CGG CCG TGC AGG AAT TCG ATA TCA AGC ermC (pER2)
ery-eag-r CCG GGC CGG CCG TCG TCG AGG TCG ACG GTA TCG ermC (pER2)
doi:10.1371/journal.ppat.1000297.t002
SR-A Protects against Meningococcal Septicaemia
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of NMB0667.
To mutate the gene NMB1220, the 59 and 39 regions of the
gene were first amplified by PCR from N. meningitidis strain MC58
chromosomal DNA, with oligonucleotide primers 1220-3f/1220-
3r and 1220-5f/1220-5r, respectively, before cloning each product
separately into pT7Blue, resulting in the plasmids pT7-1220-3 and
pT7-1220-5. The ermC cassette was amplified from pER2 [26]
with oligonucleotide primers ery-eag-f and ery-eag-r, digested with
EagI and inserted into the EagI site present within the cloned 39
region of the NMB1220 gene in pT7-1220-3 to give the construct
pT7-1220-3-ery. The cloned 39 region of NMB1220, interrupted
with ermC, was excised from pT7-1220-3-ery with XbaI and BglII
and inserted into the corresponding site within pT7-1220-5. The
resulting construct, pT7-1220-ery, was used to transform N.
meningitidis strain MC58. Transformants were screened by PCR
using oligonucleotide primers 1220-f/1220-r designed to bind
within NMB1220 to identify a transformant containing a single,
disrupted copy of NMB1220.
Resistance to the Bactericidal Effects of Human Sera
Bacteria cultured on BHI plates were assayed in pooled human
serum as described previously [27].
Cell Culture
Bone marrow-derived macrophages (BMMQ) were prepared as
described previously [7]. MQ were routinely cultured in RPMI
supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin
and 2 mM L-glutamine (PSG), 10% foetal calf serum (FCS) and
15% L-cell conditioned medium.
Uptake Assays
Bone marrow-derived macrophages were plated in 6-well
bacteriological plastic dishes at a density of 1610
6 MQ per well
24 hours before use. MQ were washed twice in PBS and then
incubated in Opti-MEM medium (Invitrogen, Paisley, UK)
containing fluorescently-labelled bacteria as specified. After
incubation with bacteria, the culture medium was removed and
the cells washed three times with PBS. Cells for flow cytometry
were harvested with PBS containing 10 mM EDTA and 4 mg/ml
lidocaine-HCl and fixed with 4% (v/v) formaldehyde in PBS.
Fluorescence was analysed on a FACScan (Becton Dickinson,
Mountain View, CA) using the FL-1 or FL-2 photomultiplier
where appropriate and the results analysed with CellQuest
software. Results are representative of at least 3 independent
experiments.
Mouse Infection Studies
A murine intraperitoneal challenge model for bacterial
clearance was employed [28]. C57BL/6J wild-type mice and a
corresponding SR-A
2/2 knock-out mouse strain were used. SR-
A
2/2 animals were developed and bred onto C57BL/6J
background using standard molecular biology techniques [12].
All animals were bred and housed under specific pathogen-free
conditions.
Meningococcal strains were grown overnight at 37uCi n5 %
CO2 on BHI plates as described above. Muller Hinton broth
(8 ml) supplemented with 0.25% (w/v) glucose in a 50 ml tissue
culture flask was inoculated with 1.2610
9 cfu from the overnight
growth resulting in an initial OD620 of ,0.1. The flask was
incubated horizontally on a gently rocking platform at 37uCi n5 %
CO2 and bacteria were cultured to mid-logarithmic growth phase,
defined as OD620 of ,0.5 (approximately 2.5 h). The bacteria
were transferred to 1.5 ml tubes and harvested by centrifugation at
1900 g for 5 min and then resuspended in PBS. The bacterial
suspensions were adjusted to the required concentration for
inoculation in BHI broth.
Bacterial doses of 1610
5 cfu/mouse were injected intraperito-
neally (i.p.) with human holo-transferrin (Sigma, 10 mg/mouse) in
a total volume of 500 ml to groups of 6–8-week-old wild-type
C57BL/6J and corresponding SR-A
2/2 knock-out inbred female
mice. At the time of infection, the actual dose delivered to each
group of mice was determined by serial dilution and replicate
colony plating. At 18 h after the initial infection, mice were
boosted i.p. with a further dose of human holo-transferrin (10 mg/
mouse in 200 ml PBS). The health of the animals was monitored
and scored at regular time points according to the symptoms
presented as follows: Healthy=5, ruffled fur=4, sticky eyes=3,
ruffled fur and sticky eyes=2, immobile=1. As soon as immobile
mice were detected they were humanely killed. Scores were then
collated and averaged for each group at the various time points
[29]; (A. Gorringe, personal communication). Survival curves were
also plotted and statistical significance determined using the Log-
rank (Mantel Cox) test. Blood samples from the tail vein (5 ml)
were taken at 20 h post-infection and serial dilutions plated to
determine bacteraemia. All dilutions were made with PBS. At
termination, blood was collected by cardiac puncture and spleens
removed. Half of each spleen was fixed in 2% paraformaldehyde
in HEPES-buffered isotonic saline for immunohistochemical
analysis. The remaining spleen was homogenized and serial
dilutions of spleen and blood were plated to determine
bacteraemia. The remaining blood was separated by centrifuga-
tion and the plasma collected and frozen at 280uC for later use.
All procedures involving animals were conducted according to the
requirements of the United Kingdom Home Office Animals
(Scientific Procedures) Acts, 1986.
Immunohistochemistry
Fixed tissues were transferred to a solution of 0.1 M sodium
phosphate buffer containing 20% sucrose, placed in Tissue-Tek
OCT compound (VWR International Ltd., Lutterworth, UK) and
snap-frozen in isopentane cooled by dry ice. Frozen sections were
cut on a Leica cryostat (5 mm thick), collected onto 1.5%
gelatinized slides, air dried for 1 hour and stored at 220uC.
Sections were washed in 0.1% Triton X-100 and endogenous
peroxidase activity was quenched by incubation in PBS containing
0.01 M glucose, 0.001 M sodium azide and 40 U glucose oxidase
for 15 min at 37uC. 5% Normal rabbit serum was used as blocking
agent for non-specific binding and avidin/biotin blocking agents
(Vector Laboratories Ltd., Peterborough, UK) were employed
according to the manufacturer’s instructions. Sections were
incubated for 60 min in the respective primary antibodies or
isotype-matched controls, washed and incubated for 30 min with
the respective affinity purified biotinylated secondary antibodies.
Finally, sections were washed and incubated with the avidin-biotin
peroxidase complex (ABC elite, Vector Laboratories Ltd.,
Peterborough, UK) for 30 min and staining visualised by
incubation with 0.5 mg/ml diaminobenzidine (Polysciences Inc.,
Northampton, UK) and hydrogen peroxide in 10 mM imidazole.
Sections were counterstained with 0.1% methyl green (Vector
Laboratories Ltd. Peterborough, UK) and mounted in DPX
(VWR International Ltd., Lutterworth, UK).
Cytokine Analysis
The concentration of interleukin-6 (IL-6) in the plasma of
infected mice was determined using an OptEIA Mouse IL-6
SR-A Protects against Meningococcal Septicaemia
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manufacturer’s instructions.
Competitive Index Assay
Groups of five 6–8-week-old female wild-type C57BL/6J and
corresponding SR-A
2/2 animals were infected with 1610
6 N.
meningitidis MC58 (wild-type)+1610
6 N. meningitidis MC58-278-
1220 (mutant) i.p, along with 10 mg human holo-transferrin. The
two bacterial strains were individually grown overnight as before.
Serial dilutions of the inoculum were also plated onto both BHI
medium and BHI medium supplemented with kanamycin (which
selects for MC58-278-1220 mutant bacteria), in order to verify the
dose and ratio of wild-type to mutant bacteria. A second dose of
10 mg human holo-transferrin was injected i.p. at 18 h. The
health of the animals was monitored as before. At termination,
blood was collected by cardiac puncture and spleens removed.
Spleens were homogenized and serial dilutions of blood and spleen
samples were plated on BHI medium and BHI medium
supplemented with kanamycin. Enumeration of wild-type bacteria
and mutant bacteria allowed for the determination of the CI ratio
between wild-type and mutant bacteria using the following
formula: CI=(wild-type output/mutant output)/(wild-type in-
put/mutant input). The statistical significance of the results was
determined using the paired student’s t-test.
Results
Construction and Evaluation N. meningitidis Mutant
Strains
To investigate the importance of NMB0278, NMB0667 and
NMB1220 for recognition of N. meningitidis by SR-A, plasmids
were constructed containing each gene interrupted by insertion of
a kanamycin or erythromycin resistance cassette. The constructs
pT7-278-kan and pT7-667-ery resulted from a single PCR
product from NMB0278 and NMB0667, respectively, cloned into
pT7Blue and then interrupted with an antibiotic resistance
cassette. It is interesting to note that when a similar approach
was utilised with NMB1220, the initial pT7-1220 construct proved
to be highly unstable and consequently a two step approach of
cloning the 59 and 39 regions of the gene together with some
flanking DNA was undertaken, which proved to be successful. The
plasmids pT7-278-kan, pT7-667-ery and pT7-12220-ery were
transformed into N. meningitidis strain MC58.
The serogroup B genome sequence contains two homologues of
NMB0278, namely NMB0294 and NMB0407. To ensure that
only NMB0278 had been disrupted, specific oligonucleotide
primers were designed to bind within the kanR cassette and in
the neighbouring gene to identify transformants containing a
single, disrupted copy of NMB0278. This transformant was
designated MC58-278.
The gene NMB0667 shows low levels of homology to a
degenerate DNA methylase found elsewhere in the serogroup B
genome (NMB1223), so primers designed to bind within the ermC
cassette and in the neighbouring gene were utilised to identify
transformants containing a single, disrupted copy of NMB0667. A
number of transformants were screened using different combina-
tions of oligonucleotide primers. For each transformant containing
an interrupted copy of NMB0667, an intact copy of the gene was
present in tandem, therefore we concluded that NMB0667 is an
essential gene, and consequently we were unable to obtain a
mutant neisserial strain deficient in this protein.
Double mutants where both NMB1220 and NMB0278 had
been interrupted were constructed by transforming MC58-1220
with chromosomal DNA from MC58-278. The disruption of
NMB0278 and NMB1220 was confirmed by the use of specific
oligonucleotide primers as for the single mutants. This transfor-
mant was designated MC58-278-1220.
Characterisation of NMB Mutants
The growth of the MC58-278, MC58-1220 and MC58-278-
1220 in vitro was compared to that of the parental strain MC58.
The bacteria were grown in Muller-Hinton broth in the same
manner as for the preparation of inoculum for the mouse infection
studies, except that growth was followed over an 8 h period and
the OD620 was measured throughout (Figure 1A). All mutants
exhibited growth curve patterns indistinguishable from the parent
strain. Outer membranes were prepared from the mutants and
parental strain following growth on BHI plates overnight and
separated by T-SDS-PAGE (Figure 1B). The resulting profiles
show that no significant differences were observed in the protein
and LPS profiles. A comparison of the parental strain MC58 and
the mutant strains showed no difference in the killing effect in
pooled normal human serum (data not shown).
Distribution of NMB0278, NMB0667, and NMB1220 across
Different N. meningitidis Strains
In order to determine the distribution of these genes, a PCR
screen was undertaken using primers specific not just for the gene
under consideration, but also for its genomic location due to the
homologous reading frames present for NMB0278 and NMB0667.
107 strains were screened using the following sets of primers; 278-
out-f/278-out-r, 667-f/667-r, 667-f2/667-r and 1220-f/1220-r.
This collection of strains was highly diverse and included
representatives of disease and carriage isolates, along with well
characterised reference strains. With the exception of one invasive
disease strain, all gave a PCR product of the expected size for each
of the three genes (refer to Table 3). The one anomalous strain
demonstrated a PCR product for NMB0667 and NMB1220 but
not for NMB0278. All three genes were determined to be present
by this method in 7 N. gonorrhoeae isolates, however the distribution
was found to vary considerably when other commensal species of
Neisseria were analysed (data not shown).
Uptake of N. meningitidis Mutant Strains by Bone
Marrow–Derived Macrophages
To ascertain the in vitro macrophage uptake of wild-type
bacteria compared to that of mutant bacteria, wild-type and SR-
A
2/2 bone marrow-derived macrophages were incubated at 37uC
for 2 h with ethanol-fixed fluorescently labelled N. meningitidis
MC58 or the mutant bacteria with deletions in either NMB0278,
NMB1220 or both (MC58-278, MC58-1220 and MC58-278-
1220), respectively, at an MOI of 20:1 (Figure 2). Association of
bacteria with macrophages was measured by flow cytometry. All
the bacterial strains were taken up by wild-type macrophages,
whereas uptake was reduced by at least 70% in macrophages
lacking SR-A. However, no differences could be detected in the
association of the mutant bacteria with wild-type macrophages.
This could be attributed to the fact that there are multiple ligands
for SR-A on N. meningitidis [18] and that the gene encoding at least
one known ligand, NMB0667, could not be deleted. In addition,
the strains still contained homologues for NMB0278.
Meningococcal Septicaemia in Wild-Type versus SR-A
2/2
Mice
Since no differences could be detected between wild-type and
mutant bacteria in their interaction with SR-A in vitro, we set up an
in vivo murine septicaemia model to investigate the role of SR-A in
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doses in wild-type and SR-A
2/2 animals to determine the
intraperitoneal (i.p.) dose required to establish bacteraemia in
the blood and spleen, without causing rapid death of the animals,
so that they could be monitored over time. From these
experiments we selected a dose of 1610
5 cfu/mouse (data not
shown). Groups of six age-matched female C57BL/6J wild-type
and corresponding SR-A
2/2 knock-out mice were injected i.p.
with 1610
5 N. meningitidis MC58 cfu/mouse and 10 mg human
holo-transferrin as a bacterial iron source. N. meningitidis requires
iron for growth and is unable to sequester iron from murine
transferrin [30,31]. A second dose of human holo-transferrin was
administered i.p. at 18 h to maintain available iron levels in the
blood. Animals were monitored regularly over a period of 48 h for
symptoms of septicaemia. Each individual was assigned a health
score at each time point, according to the severity of symptoms
(animals with a score of 5 were healthy, and a score of 1 was
assigned when they were immobile, refer to materials and
methods). Scores were then collated and averaged for the group,
and the results plotted to provide a health curve (Figure 3A).
Although animals in both groups exhibited symptoms of
septicaemia, wild-type animals remained healthier, particularly
after the second injection of iron, which would support bacterial
proliferation. Survival curves (Figure 3B) also show that all the SR-
A
2/2 animals had died at 32 h, while 33% of the wild-type
animals survived beyond 48 h and recovered to full health.
Overall, SR-A
2/2 animals showed more rapid deterioration of
health and died more quickly than did wild-type animals. This
could be correlated with the observation that SR-A
2/2 animals
had higher levels of bacteraemia in their blood at both 20 h and
48 h than did wild-type animals (Figure 3C). Although there
seemed to be a trend towards higher bacterial levels in the spleens
Table 3. Screening of N. meningitidis strains for the presence of NMB0278, NMB0667, and MNB1220.
NMB0278 NMB0667 NMB1220
Disease isolates from the UK 30/30 30/30 30/30
Immunotyping strains
1 12/12 12/12 12/12
Sequenced strains
2 3/3 3/3 3/3
Carriage collection from the Czech Republic [38] 17/17 17/17 17/17
Invasive disease samples from the UK [39] 25/26 26/26 26/26
Representatives from the MLST set [40] 11/11 18/18 18/18
Other laboratory strains 8/8 8/8 8/8
1LPS immunotyping reference strains.
2Genome sequenced serogroup A, B, and C strains.
A highly diverse collection of strains representative of disease and carriage isolates and including well-characterised reference strains were screened by PCR using
specific oligonucleotide primers for the presence or absence of each of the three genes.
doi:10.1371/journal.ppat.1000297.t003
Figure 1. Growth characteristics of wild-type N. meningitidis MC58 bacteria and mutant bacteria. (A) N. meningitidis strains MC58, MC58-
278, MC58-1220, and MC58-278-1220 bacteria were grown in Muller-Hinton broth supplemented with 0.25% (w/v) glucose. Growth was followed
over an 8-h period and the OD620 was measured throughout. (B) Outer membranes were prepared from the parental strain and mutants following
growth on BHI plates overnight, and separated by T-SDS-PAGE. Lane order: 1, strain MC58; 2, strain MC58-278; 3, strain MC58-1220; 4, strain MC58-
278-1220; 5, whole cell lysate strain MC58.
doi:10.1371/journal.ppat.1000297.g001
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2/2 animals, the differences in bacteraemia between the
two strains were not statistically significant. We also measured
levels of interleukin-6 (IL-6) in plasma from blood collected at
48 h. SR-A
2/2 animals consistently showed significantly higher
levels of the pro-inflammatory cytokine IL-6 than wild-type
animals.
Spleen sections were also analysed by immunohistochemistry
with three antibodies, FA-11 (an intracellular macrophage marker,
staining macrosialin [CD68]), 7/4 Ag (a neutrophil and monocyte
marker) and MHC-II (an antibody recognising the major
histocompatibility class II molecule, a marker expressed on
resident dendritic cells and activated macrophages). FA-11
(macrosialin) is a pan-macrophage marker, indicating the
macrophage infiltration into the spleen. Staining with MHC-II
shows that the macrophages are activated. The 7/4 Ag staining
shows the infiltration of activated monocytes and polymorphonu-
clear neutrophils (Figure 4). Therefore all the splenic samples
showed a high number of infiltrating activated macrophages and
neutrophils.
Effect of N. meningitidis Mutants In Vivo
Next, we tested the mutant bacteria lacking both SR-A ligands,
NMB0278 and NMB1220, for their ability to establish septicaemia
in wild-type and SR-A
2/2 animals. Groups of eleven age-matched
female C57BL/6J wild-type and corresponding SR-A
2/2 knock-
out mice were injected i.p. with 1610
5 N. meningitidis MC58-278-
1220 cfu/mouse and 10 mg human holo-transferrin as before.
Animals were monitored regularly, assigned health scores and
their survival plotted (Figure 5A and 5B). Animals in both groups
exhibited symptoms of septicaemia, however differences observed
between wild-type and SR-A
2/2 animals when infected with wild-
type bacteria, were absent. Overall both mouse strains showed
fewer symptoms of septicaemia and had a higher survival rate
when infected with mutant MC58-278-1220 bacteria (Figure 5A
and 5B). No statistically significant differences were observed in
the levels of bacteraemia in either the blood or the spleen between
wild-type and SR-A
2/2 animals (Figure 5C). IL-6 levels were also
not statistically significantly different between wild-type and SR-
A
2/2 animals and were lower overall than in animals infected
with wild-type bacteria (Figure 5D). Therefore the SR-A-mediated
effects observed when mice were infected with wild-type bacteria
were abrogated for mutant bacteria lacking two SR-A ligands.
In Vivo Competition Assay
When MC58-278-1220 mutant bacteria were injected into wild-
type and SR-A
2/2 mice, we observed not only the abrogation of
the SR-A-mediated effect, but also that mutant bacteria seemed to
cause less severe symptoms of septicaemia and animals had a
higher survival rate. To test whether this was a bona fide
observation, we employed a competition assay to determine
whether wild-type bacteria would out-compete mutant bacteria in
vivo. To obtain a bacterial count for wild-type and mutant bacteria
in each case, we injected 1610
6 wild-type MC58 and mutant
MC58-278-1220 bacteria i.p. at a ratio of 1:1. The respective
bacterial numbers in blood and spleen were determined by
replicate plating of serial dilutions on BHI medium and BHI
medium supplemented with kanamycin, which would select for
mutant bacteria carrying the kanamycin resistance cassette used to
disrupt the gene encoding NMB0278. Table 4 shows the
competitive indices in wild-type and SR-A
2/2 animals. A
competitive index of 6.891 and 5.090 was obtained for bacterial
counts from blood and spleen from wild-type animals, respectively.
Figure 2. Uptake of wild-type N. meningitidis MC58 bacteria and mutant bacteria lacking NMB0278 (MC58-278), NMB1220 (MC58-
1220), or both NMB0278 and NMB1220 (MC58-278-1220) by murine C57BL/6J wild-type (filled bars) and corresponding SR-A
2/2
knock-out (open bars) bone marrow-derived macrophages. Macrophages were seeded on 6-well bacteriological plastic plates at 1610
6 cells/
well and incubated with RdGnX-labelled ethanol-fixed MC58 or mutants lacking the surface proteins at an MOI of 20:1 for 2 h at 37uC in the absence
of serum. The MQ were washed to remove extracellular bacteria, detached using lidocaine/EDTA, and fixed with 4% formaldehyde before analysis by
flow cytometry. Each measurement was performed in triplicate, and results are representative of at least three similar assays. The error bars represent
standard deviation. Differences are statistically significant and *** indicates p,0.001.
doi:10.1371/journal.ppat.1000297.g002
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mutant bacteria. In SR-A
2/2 animals, a competitive index of
2.781 and 1.660 was obtained from blood and spleen, respectively.
Discussion
In this study we evaluated the in vivo role of SR-A in
meningococcal septicaemia induced by N. meningitidis MC58
(serogroup B), and ascertained the role of the N. meningitidis surface
proteins, previously identified to be ligands for SR-A [18]. The
neisserial surface protein ligands were NMB0278, NMB0667 and
NMB1220. NMB1220 has been shown to be surface expressed
and similar experiments showed the surface expression of
NMB0278 and NMB0667 [32] and personal communication).
The function of these proteins is unknown, however they show
some homology to proteins identified in other bacterial species.
Sequence analysis suggests that NMB0278 has homology to E. coli
DsbA, which functions in disulphide bond formation [33].
Interestingly, the DsbA protein of Haemophilus influenzae, another
obligate human pathogen colonising the nasopharynx, has recently
been shown to be a virulence factor [34]. The C-terminus of
NMB0667 has 20% homology with the ZipA protein from E. coli,
which is involved in septum formation during cell division [35].
NMB1220 belongs to the stomatin/Mec-2 protein family, which
are oligomeric lipid raft-associated integral proteins that regulate
the function of ion channels and transporters. We constructed
deletion mutants in N. meningitidis MC58 for all three proteins,
respectively, and also generated a double mutant lacking
NMB0278 and NMB1220. We employed several approaches to
delete NMB0667, however this mutation proved lethal, which may
be linked to the possible role of NMB0667 in septum formation
during cell division. All the mutant strains showed no deficiency in
growth characteristics or LPS and protein profile. Through PCR
analysis, we showed that the genes encoding these proteins are
present in a wide variety of neisserial strains, including invasive
disease and carriage strains. Closely related homologues are also
present in other bacteria, making them ideal PAMPs (pathogen-
associated molecular patterns) and targets for PRRs. It should
however be noted that since the genes encoding these proteins are
also present in non-pathogenic bacteria and commensal strains,
the term ‘‘PAMPs’’, though commonly used in this context, could
be considered a misnomer.
In vitro uptake of the mutant bacteria by bone marrow-derived
macrophages from wild-type and SR-A
2/2 animals did not show
Figure 3. Six 6–8-week-old female C57BL/6J wild-type and corresponding SR-A
2/2 mice were injected intraperitoneally with 1610
5
N. meningitidis MC58 and 10 mg human holo-transferrin per mouse. At 18-h post-injection a second dose of 10 mg human holo-transferrin
was administered i.p. (A) The health of the animals was monitored regularly and scored at each time point according to the symptoms presented as
follows: Healthy=5, ruffled fur=4, sticky eyes=3, ruffled fur and sticky eyes=2, immobile=1. Scores were then collated for each group at each time
point, averaged and plotted. (B) The survival of each group was plotted, and the statistical curve comparison was determined using the Log-rank
(Mantel Cox) test (P=0.0305). (C) Blood was collected from the tail vein at 20 h and by cardiac puncture at termination (48 h), and serial dilutions
were plated on bacterial growth medium. Spleen segments were also collected, homogenized, and plated. Plates were incubated at 37uC, 5% CO2
overnight, and bacterial colonies counted. Counts for six individual animals in each group are plotted. Results were analysed using a two-tailed,
unpaired t test, and the star indicates a statistically significant difference (P,0.05). (D) The concentration of interleukin-6 in the plasma from infected
animals was measured at termination (48 h) using a standard ELISA assay. Individual measurements from 6 animals in each group are plotted. Results
were analysed using a two-tailed, unpaired t test, and the star indicates a statistically significant difference (P,0.05).
doi:10.1371/journal.ppat.1000297.g003
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be attributed to the fact that at least one other SR-A ligand,
NMB0667, was present, along with two NMB0278 homologues,
which could mediate recognition and uptake. Therefore, we
studied the in vivo role of SR-A in a murine model for
meningococcal septicaemia. We injected N. meningitidis MC58 into
wild-type C57BL/6J and corresponding SR-A
2/2 mice and
monitored the manifestation of symptoms of septicaemia (ruffled
fur, sticky eyes), as well as the survival of the animals. The health
of SR-A
2/2 animals consistently deteriorated more rapidly and
there was a 33% difference in survival when compared to wild-
type animals. Analysis of blood samples taken at 20 h post-
infection and at termination showed that SR-A
2/2 animals had
higher levels of bacteraemia and the pro-inflammatory cytokine,
IL-6. Induction of IL-6 is commonly associated with meningo-
coccal septicaemia in humans [36]. Although not statistically
significant, spleen samples also indicated higher bacteraemia for
SR-A
2/2 animals, and splenic sections revealed infiltration of
activated macrophages, monocytes and neutrophils. Therefore, in
this model, SR-A played an important role in clearance of N.
meningitidis MC58. This is the first report of the in vivo importance
of SR-A in a model using a Gram-negative pathogenic organism.
Subsequently, we injected the mutant bacteria lacking both
NMB0278 and NMB1220 at the same dose i.p. into wild-type and
SR-A
2/2 mice and monitored them as before. Interestingly, the
differences observed between the mouse strains when infecting
with wild-type bacteria were abrogated for mutant bacteria lacking
the two SR-A ligands, and overall less severe symptoms were
observed. Furthermore, the levels of bacteraemia and IL-6
between wild-type and SR-A
2/2 animals did not differ signifi-
cantly. Therefore the surface proteins NMB0278 and NMB1220
are at least partially implicated in the SR-A-mediated effects
observed for wild-type bacteria. We previously showed that
NMB0278 and NMB1220 are also Toll-like receptor (TLR)
agonists, and that SR-A was required for full activation of TLR
pathways (Plu ¨ddemann et al. JII, in press). Although SR-A ligation
does not directly mediate cytokine induction, the overall lower
cytokine levels in animals infected with mutant bacteria could be
linked to the absence of NMB0278 and NMB1220. The
competitive index assay confirmed that mutant bacteria were
Figure 4. Intact spleen segments from infected animals were fixed in paraformaldehyde, embedded in OCT, sectioned, and stained
with various antibodies for the infiltration of macrophages (FA-11), polymorphonuclear neutrophils, and activated monocytes (7/
4Ag) and activated macrophages (MHC-II), as described in the text. All data are representative of at least three individual experiments.
doi:10.1371/journal.ppat.1000297.g004
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inter-experimental variations. These data indicate a role for SR-A
in clearance of N. meningitidis and development of symptoms of
septicaemia. Thus far, the development and progression of
septicaemia has mainly been linked to LPS, however these data
indicate an additional role of neisserial surface protein recognition
in this process.
It is clear that the i.p. mouse challenge model described here
does not represent the natural pathogenesis of neisserial disease,
however it does model the overwhelming septicaemia that is
characteristic of invasive meningococcal disease. Since SR-A is not
expressed on polymorphonuclear neutrophils, our results signify
an important role for macrophages and SR-A in the development
and progression of meningococcal septicaemia.
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